Medical Therapy. Adverse Effects or Lack of Adverse Effects

Factors leading to supranormal cardiac index in pediatric pulmonary hypertension patients treated with parenteral prostanoid therapy

Kimberley G. Miles Paul J. Critser, Patrick D. Evers, Michelle Cash, Melissa Magness, Elizabeth Geers Meredith O’Neil, Zhiqian Gao, Nicholas J. Ollberding, Russel HirschCincinnati Children’s Hospital Medical Center and Cincinnati College of Medicine. Oregon Health and Sciences University. United States Pulmonary CirculationPulm Circ 2023;DOI: 10.1002/pul2.12264 AbstractParenteral prostanoid therapy (PPT) can result in supranormal cardiac index (SCI; […]

Factors leading to supranormal cardiac index in pediatric pulmonary hypertension patients treated with parenteral prostanoid therapy Read More »

Pulmonary Vasodilator Therapy in Pediatric Patients on Ventricular Assist Device Support: A Single-Center Experience and Proposal for Use

Jennifer E. Schramm, John C. Dykes, Rachel K. Hopper, Jeffrey A. Feinstein, David N. Rosenthal, Rebecca J. KamenyJohns Hopkins University School of Medicine. Stanford University School of Medicine.United States American Society for Artificial Internal Organs JournalASAIO J 2023; DOI: 10.1097/MAT.0000000000002023 AbstractPediatric precapillary pulmonary hypertension can develop in response to systemic atrial hypertension. Systemic atrial decompression following

Pulmonary Vasodilator Therapy in Pediatric Patients on Ventricular Assist Device Support: A Single-Center Experience and Proposal for Use Read More »

Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial

Joseph Sullivan, Lieven Lagae, J. Helen Cross, Orrin Devinsky, Renzo Guerrini, Kelly G. Knupp, Linda Laux, Marina Nikanorova, Tilman Polster, Dinesh Talwar, Berten Ceulemans, Rima Nabbout, Gail M. Farfel, Bradley S. Galer, Arnaold R. Gammaitoni, Michael Lock, Anupam Agarwal, Ingrid E. Scheffer, The FAiRE DS Study GroupUniversity of California San Francisco. University of Leuven. Great

Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial Read More »

The use of high dose octreotide in management of neonatal chylothorax: Review

M. A. AlhasoonUnaizah College of Medicine and Medical Sciences and Qassim University.Saudi Arabia Journal of Neonatal and Perinatal MedicineJ Neonatal Perinatal Med 2021; 14: 457-461DOI: 10.3233/NPM-200644 AbstractBackground: Being a rare condition, the incidence of chylothorax among neonates is low, but the mortality rate is high. In a dire effort to reduce the risk of death, octreotide treatment

The use of high dose octreotide in management of neonatal chylothorax: Review Read More »

Pulmonary vasodilators can lead to various complications in pulmonary “arterial” hypertension associated with congenital heart disease

Ayako Chida‑Nagai, Koichi Sagawa, Takao Tsujioka, Takanori Fujimoto, Kota Taniguchi, Osamu Sasaki, Gaku Izumi, Hirokuni Yamazawa, Naoki Masaki, Atsushi Manabe, Atsuhito TakedaHokkaido University. Fukuoka Children’s Hospital. Tohoku University Graduate School of Medicine.Japan Heart and VesselsHeart Vessels 2020; 35: 1307-1315DOI: 10.1007/s00380-020-01604-1 AbstractCongenital heart disease-associated pulmonary arterial hypertension (CHD-PAH) is one of the major complications in patients with CHD. A timely closure of the left-to-right shunt will generally result

Pulmonary vasodilators can lead to various complications in pulmonary “arterial” hypertension associated with congenital heart disease Read More »

Pulmonary hypertension secondary to pulmonary veno occlusive disease: Catastrophe in the catheterization laboratory

Anuj Sharma, Prashant Raviprakash Bobhate, Tanuja Karande, Ravindra Pawar, Snehal KulkarniKokilaben Dhirubhai Ambani Hospital.India Annals of Pediatric CardiologyAnn Pediatr Cardiol 2020; 13: 377-379DOI: 10.4103/apc.APC_142_20 AbstractNo Abstract Available CategoryClass I. Pulmonary Veno-occlusive Disease and Pulmonary Capillary HemangiomatosisDiagnostic Testing for Pulmonary Vascular Disease. Invasive TestingMedical Therapy. Adverse Effects or Lack of Adverse Effects Age Focus: Pediatric Pulmonary Vascular

Pulmonary hypertension secondary to pulmonary veno occlusive disease: Catastrophe in the catheterization laboratory Read More »

Adjunct Targeted Biologic Inhibition Agents to Treat Aggressive Multivessel Intraluminal Pediatric Pulmonary Vein Stenosis

Ryan Callahan, Mark W. Kieran, Christopher W. Baird, Steven D. Colan, Kimberlee Gauvreau, Chistina M. Ireland, Audrey Marshall, Laureen M. Sena, Sara O. Vargas, Kathy J. JenkinsBoston Children’s Hospital and Harvard Medical School. Floating Hospital for Children at Tufts Medical Center. UMass Memorial Medical Center.United States Journal of PediatricsJ Pediatr 2018; 198: 29-35DOI: 10.1016/j.jpeds.2018.01.029 AbstractObjective: To evaluate

Adjunct Targeted Biologic Inhibition Agents to Treat Aggressive Multivessel Intraluminal Pediatric Pulmonary Vein Stenosis Read More »

Stroke After Cardiac Catheterization in Children

Dana B. Harrar, Catherine L. Salussolia, Patrick Vittner, Amy Danehy, Sonali Sen, Robert Whitehill, Jessica H. Chao, Miya E. Bernson-Leung, Michael J. RivkinBoston Children’s Hospital.United States Pediatric NeurologyPediatr Neurol 2019; 100: 42-48DOI: 10.1016/j.pediatrneurol.2019.07.005 AbstractBackground: Children with cardiac disease are at high risk for stroke. Approximately one-quarter of strokes in children with cardiac disease occur in the peri-procedural

Stroke After Cardiac Catheterization in Children Read More »

Systemic Sirolimus to Prevent In-Stent Stenosis in Pediatric Pulmonary Vein Stenosis

Ryan Callahan, Jesse J. Esch, Grace Wang, Christina M. Ireland, Kimberlee Gauvreau, Kathy J. JenkinsBoston Children’s Hospital and Harvard Medical School.United States Pediatric CardiologyPediatr Cardiol 2020; 41: 282-289DOI: 10.1007/s00246-019-02253-6 AbstractEvaluate the efficacy of systemic sirolimus (rapamycin) in preventing in-stent stenosis (ISS) in pediatric intraluminal pulmonary vein stenosis (PVS). Report the adverse events related to sirolimus therapy.

Systemic Sirolimus to Prevent In-Stent Stenosis in Pediatric Pulmonary Vein Stenosis Read More »

A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients

David Youssef, Susan Richards, Sabine Lague, Catherine Sheppard, Jenna Smith, Erika Vorhies, Martin Hosking, Matthew Pietrosanu, Angela BatesStollery Children’s Hospital. Alberta Children’s Hospital. British Columbia Children’s Hospital. University of Alberta.Canada Frontiers in PediatricsFront Pediatr 2023; 11: DOI: 10.3389/fped.2023.1055158 AbstractIntroduction: Selexipag, an oral nonprostanoid prostaglandin receptor agonist, has led to reduced morbidity and mortality in adults with pulmonary

A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients Read More »

Scroll to Top